

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/315	A1	(11) International Publication Number: WO 98/24426 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22438 (22) International Filing Date: 3 December 1997 (03.12.97) (30) Priority Data: 08/760,054 4 December 1996 (04.12.96) US (71) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; 116th Street & Broadway, New York, NY 10027 (US). (72) Inventors: MODAK, Shanta; 184 Howland Avenue, Riveredge, NJ 07661 (US). SAMPATH, Lester; 7 Lawrence Street, Nyack, NY 10960 (US). CARAOS, Lauserpina; 89-19 184th Street, Hollis, NY 11423 (US). (74) Agents: RAYMOND, Dana, M. et al.; Baker & Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ZINC-BASED ANTIIRRITANT CREAMS (57) Abstract The present invention relates to the use of organic salts of zinc in topical formulations. Such organic salts tend to be less water soluble and therefore less likely to result in systemic toxicity, even with chronic use. In preferred embodiments, the composition of the invention comprise zinc salicylate, which provides the antiinflammatory effect of salicylate, but wherein the zinc moiety counteracts toxic effects associated with salicylate.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ZINC-BASED ANTIIRRITANT CREAMS

1. INTRODUCTION

The present invention relates to hydrophilic and hydrophobic creams which comprise .1-15 percent by weight of an organic salt of zinc as an antiirritant, and to the use of such creams in methods of preventing skin irritation. In preferred 5 embodiments, the cream comprises zinc salicylate, which may be present in combination with another zinc salt.

2. BACKGROUND OF THE INVENTION

Local skin reactions such as itching, redness and welts may occur when certain individuals who are allergic come in contact with irritants such as 10 perfumes, cosmetics, sunscreens, aerosols, plant products (e.g. poison ivy and poison oak), and latex medical gloves. Topical formulations containing antihistamines and/or corticosteroids are routinely used to treat such allergic reactions, but are not recommended for chronic use and may, themselves, lead to sensitivity reactions.

15 Several zinc compounds have been used in topical skin formulations, but the results have not, hitherto, been satisfactory. For example, creams containing zinc oxide at high concentrations (20-40 percent by weight) have been used as skin protectants, but tend to create a thick coating which is not readily washable and which is, therefore, uncomfortable to the skin.

20 Further, compositions containing readily soluble zinc acetate (at 1-2 percent by weight), combined with antihistamine, have been used to prevent local itching when used topically (e.g. "Benadryl Itch Stopping Cream", Warner Wellcome). However, chronic use of such soluble zinc compounds may potentially result in systemic toxicity. Zinc salts have also been used to block adhesion of anti- 25 irritant compounds to the skin, as set forth in PCT/US95/03744, and zinc gluconate gels have been found to exert a soothing effect.

3. SUMMARY OF THE INVENTION

The present invention relates to the use of organic salts of zinc in topical formulations. Such organic salts tend to be less water soluble than inorganic zinc salts, and are therefore less likely to result in systemic toxicity, even with chronic use. In preferred embodiments, the compositions of the invention comprise zinc salicylate, which provides the antiinflammatory effect of salicylate, but wherein the zinc moiety counteracts toxic effects associated with salicylate.

4. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compositions and methods whereby organic salts of zinc are used in antiirritant creams for topical application.

Organic salts of zinc which may be used according to the invention include, but are not limited to, zinc salicylate, zinc tannate, zinc gluconate, zinc undecylenate, zinc valerate, zinc laureate, zinc stearate, zinc caproate, zinc gallate, zinc lactate, zinc myristate, zinc palmitate, and zinc propionate. In particular embodiments, the present invention relates to the use of zinc salts of organic acids with a higher number of carbon atoms (6 and above). Unlike readily soluble zinc salts which have a higher rate of ionization (e.g. zinc acetate, zinc sulfate, zinc carbonate etc.), the zinc salts of organic acids containing 6 or more carbons exhibit a low rate of ionization of zinc. These salts act as anti-irritants by a dual mode of action: (1) they provide sustained low levels of zinc ions on the skin surface which can inactivate existing and invading irritants; and (2) because of its low ionization property, the zinc stabilizes the anionic moiety of the salts and prolongs their retention on the skin surface where they form a barrier matrix. This matrix prevents the irritant from contacting the skin surface.

The organic salts of zinc may be comprised in a cream base which may be hydrophilic or hydrophobic. Suitable cream bases include, for example and not by way of limitation, Cetaphil cream (obtainable from Galderma Laboratories, Inc., Fort Worth, TX), "Soft-Sense" (Johnson & Son, Inc., Racine, Wisconsin), "Lotion Soft" (Calgen Vestal, St. Louis, Missouri), "Curel" (Bausch & Lomb Inc., Rochester, NY), and "Purpose" (Johnson and Johnson,). For example, "Soft-Sense" is known to

contain purified water, glycerin USP, distearyldiammonium chloride, petroleum USP, isopropyl palmitate, 1-hexadecanol, tocopherol acetate (vitamin E USP), dimethicone, titanium dioxide USP, methyl paraben, propyl paraben, sodium chloride and fragrance. "Lotion Soft" is known to be a nonionic moisturizing lotion which
5 contains a mucopolysaccharide. "Curel" is known to contain deionized water, glycerine, quaternium-5, petroleum, isopropyl palmitate, 1-hexadecanol, dimethicone, sodium chloride, fragrance, methyl paraben and propyl paraben.

The concentration of organic zinc salt may vary from .1-15 percent by weight, and is preferably 1-15 percent by weight. In particular embodiments, the
10 cream may comprise 0.1-1 percent by weight of zinc salicylate, wherein one or more other organic zinc salts may optionally be present. The concentration(s) of organic zinc salt(s) present are therapeutically effective in decreasing or preventing skin irritation in a subject.

Accordingly, preferred, nonlimiting embodiments of the invention
15 provide for topical compositions comprising (a) between about 1 and 15 percent by weight (inclusive of 1 and 15 percent) of an organic zinc salt selected from the group consisting of zinc tannate, zinc undecylenate, zinc valerate, zinc laureate, zinc stearate, zinc caproate, zinc gallate, zinc lactate, zinc myristate, zinc palmitate, zinc gluconate and zinc propionate; and (b) between about 0.1 and 1 percent by weight
20 (inclusive of 0.1 and 1 percent) of zinc salicylate, in a cream base.

The present invention also provides for methods of decreasing and/or preventing irritation of the skin of a human or non-human animal subject in need of such treatment, comprising applying a cream according to the invention to at least a portion of the skin of the subject either prior to, during, or after exposure to an irritant
25 such as an allergen or inflammatory substance. In preferred, nonlimiting embodiments, the cream comprises both zinc salicylate as well as at least one other organic zinc salt.

The following nonlimiting formulations have been found to be effective: 5 percent zinc stearate in Cetaphil cream base; 5 percent zinc salicylate in
30 Cetaphil cream base; and 5 percent zinc undecylenate in Cetaphil cream base. The following formulations have been found to be especially effective: 5 percent zinc

palmitate in Cetaphil cream base; 4 percent zinc palmitate + 4 percent zinc stearate + 1 percent zinc salicylate in Cetaphil cream base; 3 percent zinc stearate + 0.5 percent zinc salicylate in Cetaphil; and 5 percent zinc stearate + 1 percent zinc salicylate in a hydrophilic cream base. Effective, but less rapidly acting, were: 5 percent zinc
5 lactate in Cetaphil cream and 5 percent zinc acetate in Cetaphil cream.

The methods and compositions of the invention may be used to decrease and/or prevent irritation caused by any substance which may produce visible or invisible (but subjective) irritation in the skin of an individual. The cream of the invention may be applied before, during and/or after exposure. Nonlimiting examples
10 of irritants include: latex or other medical gloves, coated with starch or otherwise; plant substances, such as poison ivy or poison oak; pet allergens, such as dog or cat dander; cosmetics; perfumes; pollen; detergents; disinfectants; soaps; insect bites and stings; coelenterate stings; sunscreens, etc.

5. EXAMPLES

15 A volunteer who is sensitive to latex-starch gloves tested the following creams before donning the glove. A Placebo cream was used (control) under the glove on one hand and the test cream was used on the other hand. The gloves were worn for three hours if no reaction occurred. If a reaction occurred before three hours, the gloves were removed and the reaction noted. The various zinc salts as shown in
20 Table A were incorporated into Cetaphil Moisturizing Cream (Galderma) and used for the test. Results are shown in Table A.

Table A

Effect of Topical Creams Containing Organic Zinc Salts
on Preventing Skin Reaction from Contact with Latex
Starch Gloves

5

	<u>% Zinc salts</u> <u>in cream</u>	<u>% zinc</u> <u>in cream</u>	<u>Reactions</u>
	2% Zinc salicylate	0.38	Itching, redness after 30'
	4% Zinc salicylate*	0.76	No reaction for >3 hours
10	5% zinc acetate	1.8	No reaction for >3 hours
	2% zinc acetate	0.7	Itching, redness after 30'
	5% zinc lactate	1.4	No reaction for >3 hours
	2.5% zinc lactate	0.7	Slight itching after 1 hour
	5% zinc undecylenate	0.7	Itching after 1 hour
15	5% zinc gluconate	0.7	No reaction for >3 hours
	5% zinc stearate	0.5	No reaction for >3 hours
	10% zinc gluconate*	1.4	No reaction for >3 hours
	2.5% zinc stearate	0.25	Itching after 1 hour
	2.5% zinc stearate+*	0.25 +	No reaction for >3 hours
20	1% zinc salicylate	0.19	
	2.5% zinc stearate	0.25 +	Itching after 1 hour
	+ 1% zinc acetate	0.35	
	5% zinc stearate+*	0.5	No reaction for >3 hours
	1% zinc salicylate	0.19	
25	Placebo cream	_____	Itching, Redness after 15 minutes

All the zinc salts were incorporated in Cetaphil Moisturizing Cream.

*These creams provided increased comfort and good after feel on the hand.

Soluble and sparingly soluble zinc salts such as zinc acetate and zinc lactate were effective at higher zinc concentrations (1.4% Zn and 1.8% Zinc respectively). However sparingly soluble zinc salicylate or zinc gluconate were effective at lower concentrations (0.7% zinc). The insoluble zinc stearate was
5 effective at a zinc concentrations of 0.5%.

It appears from the results that the acid moiety of the zinc salts also contribute to the anti-irritant effect. The stearate, salicylate and gluconate molecule form a protective barrier either in the form of a gel or a film matrix when topical compositions containing these compounds are applied on the hand thus preventing the
10 irritants from contacting the skin. In addition small amounts of zinc from these compounds (especially zinc gluconate and zinc stearate) stay on the surface of the skin and inactivate the irritants.

The results in Table A also show that when lower amounts of zinc salicylate and zinc stearate are used in combination, they are as effective as the single
15 compounds at higher concentrations. Moreover, addition of small amounts of zinc salicylate to either zinc gluconate or zinc stearate improves the texture of the cream, feel on the hand and relieves pain.

Evaluation of the anti-irritant effect of different zinc salts show that zinc salts of (1) long chain (e.g., greater than or equal to 6 carbons) acids such as zinc
20 gluconate (2) higher fatty acids such as zinc palmitate, zinc stearate etc., (3) aromatic acids such as zinc salicylate are highly effective as anti-irritants. Sparingly soluble or insoluble salts when used either alone or in combination appear to provide better barrier effect than soluble zinc salts. They can be used either alone or in combination.

Topical compositions containing the following zinc salts can be
25 prepared either in a hydrophilic or hydrophobic base which forms a gel or film matrix when applied on the skin surface.

TABLE B

Compounds in the Cream Base

- A Zinc gluconate - 9%
- B zinc stearate - 9%
- 5 C Zinc salicylate - 4%
- D zinc gluconate + zinc salicylate 5% + 1%
- E Zinc stearate + Zinc salicylate - 2.5% + 1%
- F Zinc stearate + Zinc salicylate - 5% + 1%
- G Zinc gluconate + Zinc stearate + Zinc salicylate -
- 10 0.5% + 2.5% + 0.5%

Compositions A, F and G in a hydrophilic cream base were tested on volunteers for the following symptoms.

TABLE C

	A	F	G
15 Insect Bite	effective	effective	effective
Prickly Heat	effective	effective	effective
Metal Sensitivity	effective	effective	effective
Plant Irritants	effective	effective	effective

- F and G were more effective. The burn and itching disappeared faster
- 20 (within 5') when these creams were applied. In the case of cream A the symptoms disappeared in 10-20'.

TABLE D

Comparisons of the following creams with regard to comfort
on the Hand When Used Under the Glove and Feel After
Washing the Cream Off

5	<u>zinc salt in cream</u>	<u>Comfort on the hand</u>		<u>After feel</u>	
		Volunteer		Volunteer	
		1	2	1	2
	A Zn Gl 9%	Good	Good	Good	Good
	F Zn st+Zn sal	Good	Good	Good	Good
10	5%+1%				
	G Zn Gl+Zn st+Zn sal	Excellent	Excellent	Good	Good
	5%+2.5%+0.5%+0.5%				

Zn st = Zinc stearate

Zn Gl = Zinc gluconate

15 Zn sal = Zinc salicylate

Various publications are cited herein which are hereby incorporated by
reference in their entireties.

CLAIMS:

1. A topical composition comprising:
 - (a) between about 1 and 15 percent by weight of an organic zinc salt selected from the group consisting of zinc tannate, zinc gluconate, zinc undecylenate,
5 zinc valerate, zinc laureate, zinc stearate, zinc caproate, zinc gallate, zinc lactate, zinc myristate, zinc palmitate and zinc propionate; and
 - (b) between about 0.1 and 1 percent by weight of zinc salicylate;
in a cream base.
2. The composition of claim 1 wherein the cream base is hydrophobic.
- 10 3. The composition of claim 1 wherein the cream base is hydrophilic.
4. A method for preventing irritation of the skin of a subject comprising applying a therapeutically effective amount of an antiirritant cream to at least a portion of the skin of the subject prior to exposure to an irritant, wherein the antiirritant cream comprises:
 - 15 (a) between about 1 and 15 percent by weight of an organic zinc salt selected from the group consisting of zinc tannate, zinc gluconate, zinc undecylenate, zinc valerate, zinc laureate, zinc stearate, zinc caproate, zinc gallate, zinc lactate, zinc myristate, zinc palmitate and zinc propionate; and
 - (b) between about 0.1 and 1 percent by weight of zinc salicylate;
20 in a cream base.
5. A method for decreasing irritation of the skin of a subject comprising applying a therapeutically effective amount of an antiirritant cream to at least a portion of the skin of the subject, wherein the antiirritant cream comprises
 - (a) between about 1 and 15 percent by weight of an organic zinc salt
25 selected from the group consisting of zinc tannate, zinc gluconate, zinc undecylenate, zinc valerate, zinc laureate, zinc stearate, zinc caproate, zinc gallate, zinc lactate, zinc myristate, zinc palmitate and zinc propionate; and
 - (b) between about 0.1 and 1 percent by weight of zinc salicylate;
in a cream base.
- 30 6. The method of claim 5, wherein the antiirritant cream is applied prior to exposure to an irritant.

7. The method of claim 5, wherein the antiirritant cream is applied during exposure to an irritant.

8. The method of claim 5, wherein the antiirritant cream is applied after an irritant.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/22438

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/315

US CL : 514/494

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/494

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,059,416 A (CHERUKURI et al.) 22 October 1991, see claims 1 and 3-18.	1-3
Y	US 4,889,844 A (SILVETTI, Sr. et al.) 26 December 1989, see claim 1, column 5, lines 62-68, column 6, lines 47-51, column 7, line 1.	1-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 MARCH 1998

Date of mailing of the international search report

14 APR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN PAK

Telephone No. (703) 308-1235